BR9712971A - Método para produção de uma vacina para proteção de um hospedeiro contra doença causada com uma cadeia de chlamydia e composição imunológica - Google Patents

Método para produção de uma vacina para proteção de um hospedeiro contra doença causada com uma cadeia de chlamydia e composição imunológica

Info

Publication number
BR9712971A
BR9712971A BR9712971-2A BR9712971A BR9712971A BR 9712971 A BR9712971 A BR 9712971A BR 9712971 A BR9712971 A BR 9712971A BR 9712971 A BR9712971 A BR 9712971A
Authority
BR
Brazil
Prior art keywords
momp
chlamydia
host
vaccine
protect
Prior art date
Application number
BR9712971-2A
Other languages
English (en)
Inventor
Robert C Brunham
Original Assignee
Univ Manitoba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Manitoba filed Critical Univ Manitoba
Publication of BR9712971A publication Critical patent/BR9712971A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/295—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Chlamydiales (O)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"MéTODO PARA PRODUçãO DE UMA VACINA PARA PROTEçãO DE UM HOSPEDEIRO CONTRA DOENçA CAUSADA COM UMA CADEIA DE CHLAMYDIA E COMPOSIçãO IMUNOLóGICA". ácido nucléico, incluindo DNA, imunização para gerar um replicante imune para proteção em um hospedeiro, incluindo seres humanos, para uma proteína de membrana externa principal de uma cadeia de Chlamydia, preferivelmente uma seq³ência de nucleotídeos codificando um MOMP ou fragmento de MOMP que gera anticorpos que especialmente reagem com MOMP e uma seq³ência operacionalmente acoplada a primeira seq³ência para expressão do MOMP no hospedeiro. O vetor não replicante pode ser formulado com um carreador farmaceuticamente aceitável para administração "in vivo" no hospedeiro.
BR9712971-2A 1996-07-12 1997-07-11 Método para produção de uma vacina para proteção de um hospedeiro contra doença causada com uma cadeia de chlamydia e composição imunológica BR9712971A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2160796P 1996-07-12 1996-07-12
PCT/CA1997/000500 WO1998002546A2 (en) 1996-07-12 1997-07-11 Dna immunization against chlamydia infection

Publications (1)

Publication Number Publication Date
BR9712971A true BR9712971A (pt) 2002-05-07

Family

ID=21805154

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9712971-2A BR9712971A (pt) 1996-07-12 1997-07-11 Método para produção de uma vacina para proteção de um hospedeiro contra doença causada com uma cadeia de chlamydia e composição imunológica

Country Status (9)

Country Link
EP (1) EP0915978B1 (pt)
JP (1) JP2000503325A (pt)
AT (1) ATE312920T1 (pt)
AU (1) AU723235B2 (pt)
BR (1) BR9712971A (pt)
CA (1) CA2259595C (pt)
DE (1) DE69734882T2 (pt)
NZ (1) NZ334114A (pt)
WO (1) WO1998002546A2 (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696421B2 (en) 1996-07-12 2004-02-24 University Of Manitoba DNA immunization against chlamydia infection
US6344202B1 (en) 1996-07-12 2002-02-05 University Of Manitoba DNA immunization against chlaymdia infection
US6340463B1 (en) 1996-08-14 2002-01-22 Vanderbilt University Identification of antigenic peptide sequences
US6838552B1 (en) 1997-08-14 2005-01-04 Vanderbilt University Diagnosis and management of infection caused by Chlamydia
WO2000006739A2 (en) * 1998-07-27 2000-02-10 Connaught Laboratories Limited Chlamydia antigens and corresponding dna fragments and uses thereof
US20030147924A1 (en) * 1998-07-27 2003-08-07 Aventis Pasteur Limited/Aventis Pasteur Limitee Chlamydia antigens and corresponding dna fragments and uses thereof
CA2336534A1 (en) * 1998-07-27 2000-02-10 Connaught Laboratories Limited Chlamydia antigens and corresponding dna fragments and uses thereof
US6693087B1 (en) 1998-08-20 2004-02-17 Aventis Pasteur Limited Nucleic acid molecules encoding POMP91A protein of Chlamydia
CA2340283A1 (en) * 1998-08-20 2000-03-02 Aventis Pasteur Limited Nucleic acid molecules encoding pomp91a protein of chlamydia
US6403101B1 (en) * 1998-10-28 2002-06-11 Connaught Laboratories Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
US6649370B1 (en) * 1998-10-28 2003-11-18 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
US6403102B1 (en) * 1998-10-29 2002-06-11 Connaught Laboratories Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
AU3790900A (en) * 1998-12-01 2000-06-19 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
EP1169465B1 (en) 1998-12-04 2006-03-01 University Of Manitoba Two-step immunization procedure against chlamydia infection
US6447779B1 (en) 1998-12-08 2002-09-10 Corixa Corporation Compounds for the diagnosis of Chlamydial infection
US20020061848A1 (en) 2000-07-20 2002-05-23 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
US6432916B1 (en) 1998-12-08 2002-08-13 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US6555115B1 (en) 1998-12-08 2003-04-29 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
IL143531A0 (en) * 1998-12-08 2002-04-21 Corixa Corp Polypeptides containing an antigenic portion of a chlamydia antigen, dna sequences encoding said polypeptides and pharmaceutical compositions and vaccines containing the same
US6448234B1 (en) 1998-12-08 2002-09-10 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US6565856B1 (en) 1998-12-08 2003-05-20 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US6808713B1 (en) 1998-12-28 2004-10-26 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
ATE384738T1 (de) * 1998-12-28 2008-02-15 Aventis Pasteur Chlamydia antigene, entsprechende dna fragmente und ihre verwendungen
AU781995B2 (en) * 1999-05-01 2005-06-23 Genaera Corporation Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
US6811783B1 (en) 1999-09-07 2004-11-02 Aventis Pasteur Limited Immunogenic compositions for protection against chlamydial infection
JP4667694B2 (ja) 1999-09-20 2011-04-13 サノフィ、パストゥール、リミテッド クラミジア抗原および対応するｄｎａ断片ならびにその使用
US6632663B1 (en) 1999-09-22 2003-10-14 Aventis Pasteur Limited DNA immunization against chlamydia infection
EP1240331B1 (en) * 1999-12-22 2010-04-07 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
AU2138501A (en) * 1999-12-22 2001-07-03 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
AU2138601A (en) * 1999-12-22 2001-07-03 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
US20010048927A1 (en) 2000-02-01 2001-12-06 Richard Stephens Porin B (PorB) as a therapeutic target for prevention and treatment of infection by chlamydia
EP1278855B1 (en) 2000-04-21 2008-03-12 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US6919187B2 (en) 2000-04-21 2005-07-19 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US7105171B2 (en) 2002-03-07 2006-09-12 The Regents Of The University Of California Porin B (PorB) as a therapeutic target for prevention and treatment of infection by Chlamydia
CN103068837B (zh) 2010-05-28 2015-06-24 斯匹遐生物技术公司 嵌合momp抗原、方法和使用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3650571T2 (de) * 1985-01-14 1997-02-27 Chiron Corp Hauptprotein der Aussenmembran von Chlamydia

Also Published As

Publication number Publication date
WO1998002546A2 (en) 1998-01-22
DE69734882D1 (de) 2006-01-19
EP0915978A2 (en) 1999-05-19
DE69734882T2 (de) 2006-08-17
WO1998002546A3 (en) 1998-02-26
AU723235B2 (en) 2000-08-24
CA2259595C (en) 2010-11-30
NZ334114A (en) 2000-06-23
ATE312920T1 (de) 2005-12-15
CA2259595A1 (en) 1998-01-22
EP0915978B1 (en) 2005-12-14
AU3431497A (en) 1998-02-09
JP2000503325A (ja) 2000-03-21

Similar Documents

Publication Publication Date Title
BR9712971A (pt) Método para produção de uma vacina para proteção de um hospedeiro contra doença causada com uma cadeia de chlamydia e composição imunológica
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
BR9708387A (pt) Processo para vacinação de um mamìfero a um antìgeno selecionado, células patogênica e hospedeira, composição de vacina, ácido nucleico, e, opsonina engenheirada.
AU2003244855A1 (en) Method to enhance an immune response of nucleic acid vaccination
NO20010922L (no) Fremgangsmåte for DNA vaksinering
DE69632536D1 (de) Impfstoffe für das respiratorische-synzytial-virus mit nuklein säuren
HK1086750A1 (en) Pharmaceutical composition for inducing an immune response in a human or animal
WO1995029193A3 (en) Melanoma antigens
WO2001046224A3 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
BRPI0412799A (pt) imunógeno, composição, ácido nucleico, célula recombinante, métodos para preparar um polipeptìdeo, para induzir um a resposta imune protetora em um paciente e para induzir uma resposta anamnésica em um paciente, e, seqüência de ácido nucleico otimizada de levedura
BR9712556A (pt) Plasmìdeo, composição farmacêutica, e, processo de imunizar um indivìduo contra um antìgeno
GB9409985D0 (en) Vaccine against mycobacterial infections
WO1999051745A3 (en) Dna immunization against chlamydia infection
ATE251667T1 (de) Virus, welches die pankreas-krankheit bei fischen verursacht
WO2001046225A3 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
MX9801089A (es) Proteina hibrida que comprende epitopes estimulantes de celula auxiliar t y epitopes de celula b de la proteina de membrana externa mayor chlamydia trachomatis y su uso como vacuna.
BR9710849A (pt) Vacina contendo uma peróxi-redoxina e/ou uma beta-tubulina.
ATE417106T1 (de) Chlamydia antigene und deren korrespondierende dna fragmente und verwendungen davon
WO2000006742A3 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
ATE435915T1 (de) Spezifische nukleinsäuren und polypeptide aus krankheitserregenden stämmen von neisseria
BRPI0409321A (pt) antìgeno hìbrido, competição e método para induzir uma resposta imune para um agente infeccioso ou antìgeno de tumor, método para tratar uma doença infecciosa ou cáncer, e, peptìdeo
WO2000011183A3 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
MXPA01004353A (es) Antigenos de chlamydia y los correspondientes fragmentos de adn y usos de los mismos.
BR0013574A (pt) Antìgeno vacina de moraxella
WO2001046226A3 (en) Chlamydia antigens and corresponding dna fragments and uses thereof

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: DE ACORDO COM O ART 37, SUGIRO O INDEFERIMENTO DO PRESENTE PEDIDO, TENDO POR BASE OS ARTIGOS 8O, 13, 24 E 25 DA LEI 9.279 DE 14/05/1996.

B12B Appeal against refusal [chapter 12.2 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 17A ANUIDADE

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2291 DE 02/12/2014.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI